Novartis | NOVN - Current Liabilities


Novartis reported $31.37B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Alcon AG USD 3B 45M Mar/2026
Almirall EUR 350.64M 52.12M Dec/2025
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
Autolus Therapeutics Ltd USD 63.6M 9.84M Mar/2026
Bayer EUR 33.46B 875M Mar/2026
Biogen USD 3B 350.5M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Fresenius EUR 8.38B 1.18B Dec/2025
Fresenius Medical Care EUR 6.73B 484.42M Mar/2026
Genmab DKK 1.43B 686M Dec/2025
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
GRIFOLS EUR 2.12B 105M Mar/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
J&J USD 57.72B 3.59B Mar/2026
Lakefront Biotherapeutics EUR 100.42M 52.44M Mar/2026
Lonza CHF 3.57B 421M Dec/2025
Merck EUR 9.35B 307M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Novo Nordisk DKK 225.16B 9.5B Mar/2026
Orion EUR 798.6M 238.3M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Philips EUR 7.43B 78M Mar/2026
Recordati EUR 1.37B 315.51M Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 30.01B 1.66B Mar/2026
UCB EUR 4.4B 470M Dec/2025